BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 24830413)

  • 21. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
    Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
    Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
    Klein C; Bueler H; Mulligan RC
    J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.
    Stoppacciaro A; Paglia P; Lombardi L; Parmiani G; Baroni C; Colombo MP
    Eur J Immunol; 1997 Sep; 27(9):2375-82. PubMed ID: 9341783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
    Li B; VanRoey MJ; Jooss K
    Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
    Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
    Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GM-CSF expands dendritic cells and their progenitors in mouse liver.
    Pillarisetty VG; Miller G; Shah AB; DeMatteo RP
    Hepatology; 2003 Mar; 37(3):641-52. PubMed ID: 12601362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARĪ³ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
    Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
    Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
    Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
    Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.